LIST OF TABLES
TABLE 1. GLOBAL CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 2. CAR T-CELL THERAPY MARKET SIZE, FOR AXICABTAGENE CILOLEUCEL, BY REGION, 2021-2031 ($MILLION)
TABLE 3. CAR T-CELL THERAPY MARKET FOR AXICABTAGENE CILOLEUCEL BY COUNTRY, 2021-2031 ($MILLION)
TABLE 4. CAR T-CELL THERAPY MARKET SIZE, FOR TISAGENLECLEUCEL, BY REGION, 2021-2031 ($MILLION)
TABLE 5. CAR T-CELL THERAPY MARKET FOR TISAGENLECLEUCEL BY COUNTRY, 2021-2031 ($MILLION)
TABLE 6. CAR T-CELL THERAPY MARKET SIZE, FOR BREXUCABTAGENE AUTOLEUCEL, BY REGION, 2021-2031 ($MILLION)
TABLE 7. CAR T-CELL THERAPY MARKET FOR BREXUCABTAGENE AUTOLEUCEL BY COUNTRY, 2021-2031 ($MILLION)
TABLE 8. CAR T-CELL THERAPY MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 9. CAR T-CELL THERAPY MARKET FOR OTHERS BY COUNTRY, 2021-2031 ($MILLION)
TABLE 10. GLOBAL CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 11. CAR T-CELL THERAPY MARKET SIZE, FOR LYMPHOMA, BY REGION, 2021-2031 ($MILLION)
TABLE 12. CAR T-CELL THERAPY MARKET FOR LYMPHOMA BY COUNTRY, 2021-2031 ($MILLION)
TABLE 13. CAR T-CELL THERAPY MARKET SIZE, FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2021-2031 ($MILLION)
TABLE 14. CAR T-CELL THERAPY MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA BY COUNTRY, 2021-2031 ($MILLION)
TABLE 15. CAR T-CELL THERAPY MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
TABLE 16. CAR T-CELL THERAPY MARKET FOR OTHERS BY COUNTRY, 2021-2031 ($MILLION)
TABLE 17. GLOBAL CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 18. CAR T-CELL THERAPY MARKET SIZE, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
TABLE 19. CAR T-CELL THERAPY MARKET FOR HOSPITALS BY COUNTRY, 2021-2031 ($MILLION)
TABLE 20. CAR T-CELL THERAPY MARKET SIZE, FOR CANCER TREATMENT CENTERS, BY REGION, 2021-2031 ($MILLION)
TABLE 21. CAR T-CELL THERAPY MARKET FOR CANCER TREATMENT CENTERS BY COUNTRY, 2021-2031 ($MILLION)
TABLE 22. CAR T-CELL THERAPY MARKET, BY REGION, 2021-2031 ($MILLION)
TABLE 23. NORTH AMERICA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 24. NORTH AMERICA CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 25. NORTH AMERICA CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 26. NORTH AMERICA CAR T-CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 27. U.S. CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 28. U.S. CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 29. U.S. CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 30. CANADA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 31. CANADA CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 32. CANADA CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 33. EUROPE CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 34. EUROPE CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 35. EUROPE CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 36. EUROPE CAR T-CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 37. GERMANY CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 38. GERMANY CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 39. GERMANY CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 40. FRANCE CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 41. FRANCE CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 42. FRANCE CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 43. U.K. CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 44. U.K. CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 45. U.K. CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 46. REST OF EUROPE CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 47. REST OF EUROPE CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 48. REST OF EUROPE CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 49. ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 50. ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 51. ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 52. ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 53. JAPAN CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 54. JAPAN CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 55. JAPAN CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 56. CHINA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 57. CHINA CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 58. CHINA CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 59. REST OF ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 60. REST OF ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 61. REST OF ASIA-PACIFIC CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 62. LAMEA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 63. LAMEA CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 64. LAMEA CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 65. LAMEA CAR T-CELL THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
TABLE 66. LATIN AMERICA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 67. LATIN AMERICA CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 68. LATIN AMERICA CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 69. MIDDLE EAST AND AFRICA CAR T-CELL THERAPY MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
TABLE 70. MIDDLE EAST AND AFRICA CAR T-CELL THERAPY MARKET, BY INDICATION, 2021-2031 ($MILLION)
TABLE 71. MIDDLE EAST AND AFRICA CAR T-CELL THERAPY MARKET, BY END USER, 2021-2031 ($MILLION)
TABLE 72.AUTOLUS THERAPEUTICS: COMPANY SNAPSHOT
TABLE 73.AUTOLUS THERAPEUTICS: OPERATING SEGMENTS
TABLE 74.AUTOLUS THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 75.AUTOLUS THERAPEUTICS: NET SALES,
TABLE 76.AUTOLUS THERAPEUTICS: KEY STRATERGIES
TABLE 77.BLUEBIRD BIO, INC.: COMPANY SNAPSHOT
TABLE 78.BLUEBIRD BIO, INC.: OPERATING SEGMENTS
TABLE 79.BLUEBIRD BIO, INC.: PRODUCT PORTFOLIO
TABLE 80.BLUEBIRD BIO, INC.: NET SALES,
TABLE 81.BLUEBIRD BIO, INC.: KEY STRATERGIES
TABLE 82.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 83.BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
TABLE 84.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 85.BRISTOL-MYERS SQUIBB: NET SALES,
TABLE 86.BRISTOL-MYERS SQUIBB: KEY STRATERGIES
TABLE 87.CARIBOU BIOSCIENCES, INC.: COMPANY SNAPSHOT
TABLE 88.CARIBOU BIOSCIENCES, INC.: OPERATING SEGMENTS
TABLE 89.CARIBOU BIOSCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 90.CARIBOU BIOSCIENCES, INC.: NET SALES,
TABLE 91.CARIBOU BIOSCIENCES, INC.: KEY STRATERGIES
TABLE 92.CARTESIAN THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 93.CARTESIAN THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE 94.CARTESIAN THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 95.CARTESIAN THERAPEUTICS, INC.: NET SALES,
TABLE 96.CARTESIAN THERAPEUTICS, INC.: KEY STRATERGIES
TABLE 97.CELGENE CORPORATION: COMPANY SNAPSHOT
TABLE 98.CELGENE CORPORATION: OPERATING SEGMENTS
TABLE 99.CELGENE CORPORATION: PRODUCT PORTFOLIO
TABLE 100.CELGENE CORPORATION: NET SALES,
TABLE 101.CELGENE CORPORATION: KEY STRATERGIES
TABLE 102.CELLECTIS: COMPANY SNAPSHOT
TABLE 103.CELLECTIS: OPERATING SEGMENTS
TABLE 104.CELLECTIS: PRODUCT PORTFOLIO
TABLE 105.CELLECTIS: NET SALES,
TABLE 106.CELLECTIS: KEY STRATERGIES
TABLE 107.CELYAD ONCOLOGY: COMPANY SNAPSHOT
TABLE 108.CELYAD ONCOLOGY: OPERATING SEGMENTS
TABLE 109.CELYAD ONCOLOGY: PRODUCT PORTFOLIO
TABLE 110.CELYAD ONCOLOGY: NET SALES,
TABLE 111.CELYAD ONCOLOGY: KEY STRATERGIES
TABLE 112.GILEAD SCIENCES, INC. (KITE PHARMA INC.): COMPANY SNAPSHOT
TABLE 113.GILEAD SCIENCES, INC. (KITE PHARMA INC.): OPERATING SEGMENTS
TABLE 114.GILEAD SCIENCES, INC. (KITE PHARMA INC.): PRODUCT PORTFOLIO
TABLE 115.GILEAD SCIENCES, INC. (KITE PHARMA INC.): NET SALES,
TABLE 116.GILEAD SCIENCES, INC. (KITE PHARMA INC.): KEY STRATERGIES
TABLE 117.INTELLIA THERAPEUTICS: COMPANY SNAPSHOT
TABLE 118.INTELLIA THERAPEUTICS: OPERATING SEGMENTS
TABLE 119.INTELLIA THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 120.INTELLIA THERAPEUTICS: NET SALES,
TABLE 121.INTELLIA THERAPEUTICS: KEY STRATERGIES
TABLE 122.JUNO THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 123.JUNO THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE 124.JUNO THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 125.JUNO THERAPEUTICS, INC.: NET SALES,
TABLE 126.JUNO THERAPEUTICS, INC.: KEY STRATERGIES
TABLE 127.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 128.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 129.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 130.MERCK & CO., INC.: NET SALES,
TABLE 131.MERCK & CO., INC.: KEY STRATERGIES
TABLE 132.MILTENYI BIOTECH: COMPANY SNAPSHOT
TABLE 133.MILTENYI BIOTECH: OPERATING SEGMENTS
TABLE 134.MILTENYI BIOTECH: PRODUCT PORTFOLIO
TABLE 135.MILTENYI BIOTECH: NET SALES,
TABLE 136.MILTENYI BIOTECH: KEY STRATERGIES
TABLE 137.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 138.NOVARTIS AG: OPERATING SEGMENTS
TABLE 139.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 140.NOVARTIS AG: NET SALES,
TABLE 141.NOVARTIS AG: KEY STRATERGIES
TABLE 142.PFIZER, INC.: COMPANY SNAPSHOT
TABLE 143.PFIZER, INC.: OPERATING SEGMENTS
TABLE 144.PFIZER, INC.: PRODUCT PORTFOLIO
TABLE 145.PFIZER, INC.: NET SALES,
TABLE 146.PFIZER, INC.: KEY STRATERGIES
TABLE 147.SORRENTO THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 148.SORRENTO THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE 149.SORRENTO THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 150.SORRENTO THERAPEUTICS, INC.: NET SALES,
TABLE 151.SORRENTO THERAPEUTICS, INC.: KEY STRATERGIES LIST OF FIGURES
FIGURE 1.CAR T-CELL THERAPY MARKET SEGMENTATION
FIGURE 2.CAR T-CELL THERAPY MARKET,2021-2031
FIGURE 3.CAR T-CELL THERAPY MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.CAR T-CELL THERAPY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.CAR T-CELL THERAPY MARKET,BY DRUG TYPE,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF AXICABTAGENE CILOLEUCEL CAR T-CELL THERAPY MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF TISAGENLECLEUCEL CAR T-CELL THERAPY MARKET,2021-2031(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF BREXUCABTAGENE AUTOLEUCEL CAR T-CELL THERAPY MARKET,2021-2031(%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHERS CAR T-CELL THERAPY MARKET,2021-2031(%)
FIGURE 17.CAR T-CELL THERAPY MARKET,BY INDICATION,2021(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF LYMPHOMA CAR T-CELL THERAPY MARKET,2021-2031(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ACUTE LYMPHOCYTIC LEUKEMIA CAR T-CELL THERAPY MARKET,2021-2031(%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS CAR T-CELL THERAPY MARKET,2021-2031(%)
FIGURE 21.CAR T-CELL THERAPY MARKET,BY END USER,2021(%)
FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITALS CAR T-CELL THERAPY MARKET,2021-2031(%)
FIGURE 23.COMPARATIVE SHARE ANALYSIS OF CANCER TREATMENT CENTERS CAR T-CELL THERAPY MARKET,2021-2031(%)
FIGURE 24.CAR T-CELL THERAPY MARKET BY REGION,2021
FIGURE 25.U.S. CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 26.CANADA CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 27.GERMANY CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 28.FRANCE CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 29.U.K. CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 30.REST OF EUROPE CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 31.JAPAN CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 32.CHINA CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 33.REST OF ASIA-PACIFIC CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 34.LATIN AMERICA CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 35.MIDDLE EAST AND AFRICA CAR T-CELL THERAPY MARKET,2021-2031($MILLION)
FIGURE 36. TOP WINNING STRATEGIES, BY YEAR
FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 39.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 40.COMPETITIVE DASHBOARD
FIGURE 41.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 42.AUTOLUS THERAPEUTICS.: NET SALES ,($MILLION)
FIGURE 43.BLUEBIRD BIO, INC..: NET SALES ,($MILLION)
FIGURE 44.BRISTOL-MYERS SQUIBB.: NET SALES ,($MILLION)
FIGURE 45.CARIBOU BIOSCIENCES, INC..: NET SALES ,($MILLION)
FIGURE 46.CARTESIAN THERAPEUTICS, INC..: NET SALES ,($MILLION)
FIGURE 47.CELGENE CORPORATION.: NET SALES ,($MILLION)
FIGURE 48.CELLECTIS.: NET SALES ,($MILLION)
FIGURE 49.CELYAD ONCOLOGY.: NET SALES ,($MILLION)
FIGURE 50.GILEAD SCIENCES, INC. (KITE PHARMA INC.).: NET SALES ,($MILLION)
FIGURE 51.INTELLIA THERAPEUTICS.: NET SALES ,($MILLION)
FIGURE 52.JUNO THERAPEUTICS, INC..: NET SALES ,($MILLION)
FIGURE 53.MERCK & CO., INC..: NET SALES ,($MILLION)
FIGURE 54.MILTENYI BIOTECH.: NET SALES ,($MILLION)
FIGURE 55.NOVARTIS AG.: NET SALES ,($MILLION)
FIGURE 56.PFIZER, INC..: NET SALES ,($MILLION)
FIGURE 57.SORRENTO THERAPEUTICS, INC..: NET SALES ,($MILLION